Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naïve Participants

NCT05975060 is registered in ClinicalTrials.gov with Novavax as lead sponsor.

NCT NCT05975060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05975060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naïve Participants
Lead sponsor
Novavax
Phase
Phase 2/3
Overall status
Completed
Start date
September 7, 2023
Completion date
May 20, 2024
Enrollment
660 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19